Immune-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy

AIDS

Volumn 13, Issue 17, 1999, Pages 2405-2410

  Prins, Jan M ^a,e   Jurriaans, Suzanne ^b   Van Praag, Rieneke M E ^a   Blaak, Hetty ^c   Van Rij, Ronald ^c   Schellekens, Peter Th A ^b   Ten Berge, Ineke J M ^b   Yong, Si La ^b   Fox, Cecil H ^d   Roos, Marijke T L ^c   De Wolf, Frank ^b   Goudsmit, Jaap ^b   Schuitemaker, Hanneke ^c   Lange, Joep M A ^a,b  

^a Division of Infectious Diseases   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

^d Molecular Histology Labs   (United States)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Activation; Anti CD3; Clinical trials; Cytokines; HIV 1; IL 2; Immune based therapy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD3 ANTIGEN; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; NEVIRAPINE; OKT 3; RECOMBINANT INTERLEUKIN 2; RITONAVIR; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTERLEUKIN 2; RECOMBINANT PROTEIN; VIRUS DNA;

ANEMIA; ARTICLE; CASE REPORT; DIARRHEA; FEVER; HEADACHE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; KIDNEY FAILURE; LYMPHOCYTE PROLIFERATION; NAUSEA; PRIORITY JOURNAL; SEIZURE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIREMIA; BLOOD; DRUG EFFECT; GENETICS; IMMUNOLOGY; IN SITU HYBRIDIZATION; ISOLATION AND PURIFICATION; LYMPH NODE; LYMPHOCYTE ACTIVATION; VIROLOGY; VIRUS REPLICATION;

ANTI-HIV AGENTS; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; IN SITU HYBRIDIZATION; INTERLEUKIN-2; LYMPH NODES; LYMPHOCYTE ACTIVATION; MUROMONAB-CD3; RECOMBINANT PROTEINS; RNA, VIRAL; T-LYMPHOCYTES; VIREMIA; VIRUS REPLICATION;

EID: 0033520846     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199912030-00012     Document Type: Article

References (31)

1. 1. Wong JK, Hezareth M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
2. 2. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
3. 3. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999, 5:512-517.
4. 4. Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998, 12:1735-1744.
5. 5. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-58.
6. 6. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998, 188:83-91.
7. 7. Ho DD. Towards HIV eradication or remission: the tasks ahead. Science 1998, 280:1866-1867.
8. 8. Green DR, Scott DW. Activation-induced apoptosis in lymphocytes. Curr Opin Immunol 1994, 6:476-487.
9. 9. Ellenhorn JDI, Hirsch R, Schreiber H, Bluestone JA. In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science 1988, 242:569-571.
10. 10. Ellenhorn JDI, Woodle ES, Ghobreal I, Thistlethwaite JR, Bluestone JA. Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Transplantation 1990, 50:608-612.
11. 11. Meuer SC, Hussey RE, Cantrell DA, et al. Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway. Proc Natl Acad Sci U S A 1984, 81:1509-1513.
12. 12. Weverling GJ, Lange JMA, Jurriaans S, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998, 12:F117-122.
13. 13. Buysmann S, Hack CF, van Diepen FNJ, Surachno J, ten Berge IJM. Administration of OKT3 as a two-hour infusion attenuates first-dose side effects. Transplantation 1997, 64:1620-1623.
14. 14. Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach JF. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 1986, 137:830-838.
15. 15. Fox CH, Cottler-Fox M. In situ hybridization for the detection of HIV RNA in cells and tissues. In: Current protocols in immunology. Coligan J, Kruisbeek A, Margulies D, Shevach E, Strober W (editors). New York: Wiley; 1993.
16. 16. Fox CH, Hoover S, Currall VR, Bahre HJ, Cottler-Fox M, HIV in infected lymph nodes. Nature 1994, 370:256.
17. 17. Bruisten SM, Frissen PH, van Swieten P, et al. Prospective longitudinal analysis of viral load and surrogate markers in relation to clinical progression in HIV type-1 infected persons. AIDS Res Hum Retroviruses 1997, 13:327-335.
18. 18. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188.
19. 19. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995, 1:1284-1290.
20. 20. Koot M, van 't Wout AB, Kootstra NA, de Goede REY, Lersmette M, Schuitemaker H. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis 1996, 173:349-354.
21. 21. Mercatello A, Hadj-Aïssa A, Negrier S, et al. Acute renal failure with preserved renal plasma flow induced by cancer immunotherapy. Kidney Int 1991, 40:309-314.
22. 22. Shalmi CL, Dutcher JP, Feinfeld DA, et al. Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion. J Clin Oncol 1990, 8:1839-1846.
23. 23. Memoli B, De Nicola L, Libella C, et al. Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion. Am J Kidney Dis 1995, 26:27-33.
24. 24. van Laar JM, van Buchem MA, Weyl N, Cleton FJ. Reversible neurotoxicity during interleukin-2 therapy for metastatic renal cell carcinoma. Eur J Cancer 1995, 31A:1895-1897.
25. 25. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996, 335:1350-1356.
26. 26 Suthanthiran M, Wiebe ML, Stenzel KH. Effect of immunosuppressants on OKT3 associated T cell activation: clinical implications. Kidney Int 1987, 32:362-367.
27. 27, Van Praag M, Prins J, Ten Berge I, Schellekens P, Lange J. Cytokine and chemokine levels in HIV-1 positive patients treated with anti-CD3 monoclonal antibody (OKT3) and recombinant IL-2. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract 29].
28. 28. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Transplantation 1990, 49:697-702.
29. 29. Goumy L, Ferran C, Merite S, Bach JF, Chatenoud L. In vivo anti-CD3-driven cell activation. Cellular source of induced tumor necrosis factor, interleukin-1 β, and interleukin-6. Transplantation 1996, 61:83-87.
30. 30. Davey RJ Jr, Chaitt DG, Piscitelli SC, et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 1997, 175:781-789.
31. 31. Thistlethwaite JR Jr, Stuart JK, Mayes JT, et al. Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1988, 11:112-119.